Cell-therapy

Delve into the world of Cell-therapy in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Cell-therapy to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Bayer's Sunharbo (Asundexian) Secures NMPA Approval in China – World's First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA
CompanyDrug

Bayer’s Sunharbo (Asundexian) Secures NMPA Approval in China – World’s First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA

Bayer AG (ETR: BAYN) announced that China's National Medical Products Administration (NMPA) has approved Sunharbo (asundexian tablets), the world's first (first‑in‑class) activated Factor XI (FXIa) inhibitor, for reducing the risk…

Hansoh Pharma Pledges RMB 100 Million Donation to the China Foundation for Science and Technology Development – Strategic Partnership to Fund Scientific Innovation, Talent Development and Health Communication

Hansoh Pharma Pledges RMB 100 Million Donation to the China Foundation for Science and Technology Development – Strategic Partnership to Fund Scientific Innovation, Talent Development and Health Communication

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

JW Therapeutics Presents Carteyva Data at ASH Annual Meeting

CompanyDrug

ASH 2022: China Biotechs Showcase Latest Clinical Trial Results

CompanyDeals

ExoNeuglia Secures Angel Funding for iPSC-Based Cell Therapy

CompanyDeals

ST Phi Therapeutics Partners with Azenta Life Sciences to Advance Cell Therapy

CompanyDeals

Everlife Biomed Raises Pre-Series A+ Funding for Immune Exemption Platform

CompanyDeals

Kunshi Biotechnology and Puheng Technology Partner on 3D NAC-Organ Platform for CAR-Macrophage Screening

CompanyDrug

Vcanbio’s VUM02 Accepted for Review by China’s Center for Drug Evaluation

CompanyDeals

IASO Biotherapeutics Partners with Umoja Biopharma to Evaluate iCIL Platform

Show More